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Abstract
Background: Many mathematical models have investigated the impact of expanding access to antiretroviral therapy (ART)
on new HIV infections. Comparing results and conclusions across models is challenging because models have addressed
slightly different questions and have reported different outcome metrics. This study compares the predictions of several
mathematical models simulating the same ART intervention programmes to determine the extent to which models agree
about the epidemiological impact of expanded ART.
Methods and Findings: Twelve independent mathematical models evaluated a set of standardised ART intervention
scenarios in South Africa and reported a common set of outputs. Intervention scenarios systematically varied the CD4 count
threshold for treatment eligibility, access to treatment, and programme retention. For a scenario in which 80% of HIV-infected
individuals start treatment on average 1 y after their CD4 count drops below 350 cells/ml and 85% remain on treatment after
3 y, the models projected that HIV incidence would be 35% to 54% lower 8 y after the introduction of ART, compared to a
counterfactual scenario in which there is no ART. More variation existed in the estimated long-term (38 y) reductions in
incidence. The impact of optimistic interventions including immediate ART initiation varied widely across models, maintaining
substantial uncertainty about the theoretical prospect for elimination of HIV from the population using ART alone over the
next four decades. The number of person-years of ART per infection averted over 8 y ranged between 5.8 and 18.7.
Considering the actual scale-up of ART in South Africa, sevenmodels estimated that current HIV incidence is 17% to 32% lower
than it would have been in the absence of ART. Differences between model assumptions about CD4 decline and HIV
transmissibility over the course of infection explained only a modest amount of the variation in model results.
Conclusions: Mathematical models evaluating the impact of ART vary substantially in structure, complexity, and parameter
choices, but all suggest that ART, at high levels of access and with high adherence, has the potential to substantially reduce
new HIV infections. There was broad agreement regarding the short-term epidemiologic impact of ambitious treatment
scale-up, but more variation in longer term projections and in the efficiency with which treatment can reduce new
infections. Differences between model predictions could not be explained by differences in model structure or
parameterization that were hypothesized to affect intervention impact.
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Introduction
There has recently been increasing interest in expanding
provision of antiretroviral therapy (ART) as a tool for reducing
the spread of HIV in generalised epidemics in sub-Saharan Africa
[1–5]. As momentum gathers for ‘‘HIV treatment as prevention’’,
there is an urgent need to understand how ART might contribute
to averting HIV transmissions, in addition to its direct benefits in
reducing morbidity and mortality amongst treated patients.
Mathematical modelling has supplied critical insights to discus-
sions about treatment as prevention by providing a framework for
combining information about the relationship between an infected
individual’s viral load and HIV transmissibility [6,7], the reduction
in a host’s HIV viral load when on ART [8,9], and the population-
level contact structure over which HIV is transmitted [10,11].
The idea of using medicines that suppress viral concentrations
to reduce transmission of infection was posed almost as soon as the
first HIV drugs were developed [12,13]. Early models of the
impact of ART focused on the opposing effects of reduced
transmissibility and extended survival on new HIV infections, and
whether associated increases in sexual risk behaviour would negate
the prevention benefits of ART [10,12,14–23]. Since then,
longitudinal observational data and one randomized controlled
trial have demonstrated substantial reductions in the risk of
heterosexual HIV transmission when the infective partner is virally
suppressed [24–28], and continued follow-up of individuals
receiving ART has confirmed the durability of viral suppression
[29], including in sub-Saharan Africa [30,31]. At the same time,
there have been tremendous improvements in access to treatment
in sub-Saharan Africa [32]. More recent modelling has shown
more optimism about the potential for treatment to reduce new
HIV infections in this region, with much work focused on the
setting of South Africa, home to one in six people living with HIV
globally [33].
Perhaps the most provocative of these modelling efforts has
been the study by Granich and colleagues suggesting that a
strategy involving annual testing and immediate treatment for all
HIV-infected individuals, combined with other interventions,
could eliminate HIV by the year 2050 [34]. Wagner and Blower
implemented the same model but used different assumptions about
treatment uptake amongst asymptomatic infected individuals that
they characterised as being more realistic, and concluded that
elimination would not be possible [35]. Kretzschmar et al.
highlighted how choices in model structure affect the epidemic
dynamics and intervention impact [36]. Dodd et al. showed that
the potential for treatment to eliminate HIV depends on the
patterns of sexual mixing in the population [11]. An age-structured
model by Bacae¨r et al. found that elimination might be possible
with less frequent testing than proposed by Granich et al., given
recent epidemic trends and increases in condom usage [37].
Bendavid et al. used a microsimulation model to highlight that, in
addition to increasing HIV testing, improving linkage to and
retention in care are essential to achieving maximal benefits of
test-and-treat interventions [38].
Other models have focused on the potential prevention benefits
of providing treatment in line with current therapeutic guidelines.
Eaton et al. estimated that 60 to 90 new infections could be
averted for every 1,000 additional persons treated with CD4 cell
count below 350 cells/ml (the current World Health Organization
recommendation for when to start treatment [39]), depending on
how well patients on treatment are retained in care [40]. The
Goals model, used in the evaluation of the new UNAIDS
Investment Framework, found that a US$46.5 billion incremental
investment over the years 2011 to 2020, incorporating expanding
access to ART, could avert 12.2 million new infections and 7.4
million deaths globally over that period [41]. Using a micro-
simulation model of the HIV epidemic in KwaZulu-Natal
Province, Hontelez et al. found that expanding access to ART
from those with CD4 cell count #200 cells/ml to those with #350
cells/ml required 28% more patients to receive treatment, but
amounted to only a 7% increase in annual investment [42].
Cumulative net costs broke even after 16 y.
Models have also sought to understand the impact of past and
current treatment policies; Johnson et al. used the ASSA2003 and
STI-HIV Interaction models to assess the relative contributions of
increased condom usage and ART scale-up to the declines in HIV
incidence in South Africa up to 2008 [43]. Finally, other
mathematical models have been used for short-term projections
as a basis for power calculations for community-randomized trials
of treatment as prevention [44].
Each of these models has predicted dramatic epidemiologic
benefits of expanding access to ART, but models appear to diverge
in their estimates of the possibility of eventually eliminating HIV
using ART, the cost-effectiveness of increasing the CD4 threshold
for treatment eligibility, and the benefits of immediate treatment
compared to treatment based on the current World Health
Organization eligibility guidelines. Directly comparing the models’
predictions is challenging because each model has been applied to
a slightly different setting, has used different assumptions regarding
other interventions, has been used to answer different questions,
and has reported different outcome metrics.
In this study we seek to understand the extent to which diverse
mathematical models agree on the epidemiological impact of
expanded access to ART by simulating the same set of
intervention scenarios across the models and focusing on
standardised outputs. The intervention scenarios are designed to
be simple enough to be consistently implemented across different
types of models in order to control several aspects of the treatment
programme and isolate the effects of model structure, parameters,
and assumptions about the underlying epidemic on estimates of
intervention impact. The purpose of this study is not to make
predictions about the impact of any particular intervention in any
specific setting, but rather to better characterise the array of
mathematical models being used to inform policy about treatment
as prevention in hyperendemic settings such as South Africa.
Methods
Study Design
Literature and reports of meetings on related topics were
reviewed in August 2011, and researchers who had previously
developed mathematical models of the potential epidemiological
impact of expanded access to ART, calibrated to the South
African epidemic setting, were invited to participate in the model
comparison exercise by simulating a standardised set of ART
scale-up scenarios. Three aspects of the treatment programme
were systematically varied: the CD4 threshold for treatment
eligibility, access to treatment for those eligible, and the retention
of patients on treatment. The timing of ART introduction and the
rate at which individuals start treatment after becoming eligible
were also standardised. The impact of an intervention was
measured by comparing the number of new infections in the
intervention scenario with that in a counterfactual epidemic
simulation in which no ART is provided within the same model
population. The counterfactual of no ART was chosen so that
comparison between models would be independent of assumptions
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about the historic growth in ART uptake. As such, the results
should not be interpreted as estimates of the future impact of
treatment compared to current patterns of ART coverage, but can
be generally taken as estimates of the overall net impact of
treatment in a hypothetical scenario that assumes rapid ART
scale-up and a homogenous rate of ART initiation across all ART-
eligible adults. Although different models may incidentally have
been calibrated using the same data, no standardisation was
imposed on the specific epidemiologic data used for model
calibration or on the calibration procedure itself in this exercise.
Mathematical Models
Twelve groups accepted the invitation to participate in the
model comparison exercise. The collection of models encompasses
a wide range of model structures, mechanisms for representing
HIV transmission and disease progression, overall levels of
complexity, and detail in the characterisation of treatment
programmes. Table 1 summarises the names, authors, and key
references for each model, and compares aspects of model
structure. Four of the models are agent-based microsimulation
models (i.e., models that track the behaviour and infection status of
individual people) and use random-number generators to simulate
particular events such as a new partnership formation or
transmission events. The remaining eight models are deterministic
compartmental models that stratify the population into groups
according to each individual’s characteristics and HIV infection
status and use differential or difference equations to track the rate
of movement of individuals between these groups. One of the
models, the BBH model, solves the differential equations
analytically, while the others numerically evaluate the differential
equations. Ten of the models explicitly simulate both sexes and
heterosexual HIV transmission, and six of the models include
some form of age structure, although the extent to which age
affects the natural history of HIV, the risk of HIV acquisition, and
the risk of HIV transmission varies amongst these. All of the
models simulate the national HIV epidemic in South Africa except
for the STDSIM model, which simulates the higher prevalence
Hlabisa subdistrict of KwaZulu-Natal Province, South Africa. Box
1 gives further comparative description of the structures and
parameterization of the mathematical models.
Intervention Scenarios
Three different CD4 cell count thresholds for treatment
eligibility were considered: CD4 count #200 cells/ml, CD4 count
#350 cells/ml, and all HIV-infected individuals. In each eligibility
scenario, treatment initiation was simulated under the assumption
that all eligible individuals had equal access, without prioritisation
for any subpopulations. It was further assumed that eligible
individuals with access to the intervention would initiate ART at a
constant rate after reaching eligibility, such that average time from
eligibility to treatment initiation would be 1 y.
Treatment access was defined as the proportion of eligible
individuals who eventually initiate treatment. For example, 60%
access and eligibility at CD4#350 cells/ml implies that 60% of
individuals will initiate treatment, on average 1 y after their CD4
count drops below 350 cells/ml, while 40% will never access
treatment. Seven levels of treatment access were evaluated: 50%,
60%, 70%, 80%, 90%, 95%, and 100%.
Retention was defined as the percentage of individuals
remaining on treatment after 3 y, excluding from both the
numerator and the denominator those who had died while on
treatment. The levels of retention were 75%, 85%, 95%, and
100% (no dropout), with individuals dropping out from treatment
at a constant rate such that the desired level of retention was
achieved at the 3-y time point. The prognosis and future treatment
options for individuals who dropped out from treatment were not
standardised.
Intervention Scale-Up
ART was assumed to be introduced into the population from
the beginning of year 2012, with no treatment provision prior to
this (in contrast to the rapid scale-up of treatment that has actually
occurred prior to 2012 in South Africa). Intervention scale-up was
immediate—a fraction (corresponding to the specified level of
ART access) of individuals already eligible for treatment at the
start of the intervention period were assumed to initiate treatment
at a constant rate from that point, along with individuals who
became eligible for treatment after the start of the intervention
period.
Output Metrics
The measures of intervention impact were the percentage
reduction in HIV incidence rate among adults (aged 15–49 y) in
the ART scenario versus the no-ART counterfactual, the
cumulative number of person-years of ART provided since the
introduction of ART, and the cumulative number of person-years
of ART provided per infection averted as a measure of the
‘‘efficiency’’ with which ART prevents infections. The percentage
reduction in incidence was defined by calculating the difference in
the adult HIV incidence rate between the intervention and no-
ART counterfactual in the same year and dividing this by the
incidence rate in the counterfactual scenario. The number of
person-years of ART provided per infection averted was
calculated by dividing the cumulative number of person-years of
ART by the difference between the number of new adult
infections since year 2012 in the intervention and the counterfac-
tual scenario. Each of these metrics was reported at the midpoints
of the years 2020 and 2050. Most of the models included in this
study were not designed with the intention of making realistic
projections to year 2050, but these results were included to gain
some insight into the long-term dynamics of the models.
In addition to these measures of intervention impact, each
model reported the HIV prevalence and HIV incidence rate
amongst males and females aged 15–49 y for the no-treatment
counterfactual simulation and the total size of the adult population
(age 15 y and older). Each model also produced the proportion of
the HIV-infected population in each CD4 count category (#200,
200–350, and .350 cells/ml) and in early HIV infection in year
2012, and the proportion of HIV transmissions from individuals in
each category.
The Eaton and STI-HIV Interaction models report posterior
means and 95% credible intervals for model outcomes of
interest (see Box 1). The Bendavid model completed simulations
only for 50%, 80%, and 100% access, and 75%, 85%, and
100% retention scenarios, and only simulated to year 2040, so
results for this model are reported for the year 2040 where other
model results are reported for year 2050. The BBH model
completed simulations only for the 85% and 100% retention
scenarios. The Granich model did not simulate ART for the
CD4#200 cells/ml eligibility threshold, while the STI-HIV
Interaction model did not simulate ART eligibility for all HIV-
infected individuals. As a result of these models not completing
all intervention scenarios and outputs, some analyses include
only a subset of the models. To maximise comparability, the
40% reduction in transmission due to combination with other
preventive interventions assumed by Granich and colleagues in
[34] was not incorporated here.
Comparison of Models of ART as HIV Prevention
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Box 1. Comparative Description of Mathematical Models
This box elaborates on the comparison of aspects of the
models’ structure, assumptions, and parameterization pre-
sented in Table 1. Specific details about the structure and
implementation of each of the models are available in the
references included in Table 1 or from the HIV Modelling
Consortium (http://www.hivmodelling.org/plos-medicine-
special-collection).
Many of the models allow individuals to have different
propensities for sexual risk behaviour. Each of the micro-
simulation models allows individuals to have both long-term
(or marital) partnerships and short-term (or informal or
casual) partnerships that are different in duration, and
individuals have heterogeneous propensities to form short-
term partnerships. In the STDSIM model a proportion of the
population engages in commercial sex work partnerships; in
the EMOD model a proportion can have transitory partner-
ships, a third partnership type that is shorter than a casual
partnership. Among the microsimulation models, EMOD and
STDSIM explicitly simulate the sexual partnership network,
while the Bendavid and Synthesis Transmission models
calculate the risk of acquiring HIV for an individual in a
partnership by sampling the distribution of viral load across,
respectively, the entire population and potential partners.
The deterministic models assume that sexual contacts occur
instantaneously. The BBH, Granich, and HIV Portfolio models
assume that all individuals form new contacts at the same
rate and mix homogeneously. The other deterministic
models stratify the population into risk groups that form
new contacts at different rates (Eaton, Fraser, and Goals:
three groups; STI-HIV Interaction: two groups). The STI-HIV
Interaction and Goals models additionally include commer-
cial sex workers, and the Goals model includes transmission
among men who have sex with men and injecting drug
users. The STI-HIV Interaction model separates both the low-
and high-risk groups into those with short-term or long-term
partnerships or both. The Eaton, Fraser, and STI-HIV
Interaction models all include a degree of ‘‘assortative’’
mixing (preferential partnership formation with those in the
same risk group), and all partnerships are formed in the same
risk group in the Goals model, except for low-risk men and
women who are married to high-risk partners. The CD4 HIV/
ART model does not explicitly model sexual mixing but
rather calculates the number of new HIV infections by
multiplying the current number of HIV-infected adults by a
fixed force of infection calculated from the Spectrum model
projection for South Africa.
All of the models except for the Granich model simulate
different stages of HIV infection that affect the transmissi-
bility of an individual, including a period of elevated
infectiousness during the first few weeks of infection and
increased transmission during later stage infection. Param-
eters governing the relative transmissibility during early
infection are based principally on two sources: a meta-
analysis of HIV transmission per coital act by Boily et al. [68],
which estimated a 10-fold increase in transmission relative to
asymptomatic infection (BBH, CD4 HIV/ART, Goals, and STI-
HIV Interaction), or a reanalysis of data from Rakai, Uganda
[70], by Hollingsworth et al. [69], which estimated a 26-fold
increase (Eaton, EMOD, Fraser, and Synthesis Transmission).
Relative transmissibility after the early stage is according to
clinical stage (asymptomatic and AIDS: BBH, CD4 HIV/ART,
EMOD, Goals; asymptomatic, pre-AIDS, and AIDS: STDSIM,
STI-HIV Interaction) or CD4 count (Eaton, Fraser, and HIV
Portfolio). The Bendavid and Synthesis Transmission models
simulate the change in viral load for infected individuals and
associate HIV transmission with this according to an
empirically described relationship [6]. Many models assume
an increased risk of male-to-female transmission compared
to female-to-male transmission, and attenuation in female-
to-male transmission due to male circumcision. The Goals,
STDSIM, and Synthesis Transmission models include an
increased risk of HIV transmission in the presence of other
sexually transmitted infections.
The models that simulate each individual’s viral load
(Bendavid and Synthesis Transmission) mechanistically relate
reduction in transmission on treatment to the effect of ART
on viral load, while the other models all assume a reduction
in transmission of greater than 90% for individuals on ART.
The Bendavid, Eaton, and Synthesis Transmission models
simulate a period of a few months of incomplete viral
suppression after ART initiation before the full reduction in
infectiousness is achieved. These three models and EMOD
include a return to higher infectiousness during treatment
failure. The remaining models assume a fixed reduction in
transmissibility as soon as treatment is started, until either
death on ART or dropout from treatment. The Bendavid and
Synthesis Transmission models simulate switching to sec-
ond-line ART upon an immunologic (Bendavid) or virologic
(Synthesis Transmission) failure event. The Synthesis Trans-
mission model is the only model to explicitly simulate
heterogeneous adherence to treatment between patients
and the emergence and impact of resistance. The models
vary in their assumptions about what happens to an
individual after dropping out from treatment. The CD4
HIV/ART, Fraser, Goals, Granich, and HIV Portfolio models
return individuals who drop out to an untreated state,
allowing them to restart treatment in exactly the same
manner as those that have never been treated, while the
Bendavid, STDSIM, STI-HIV Interaction, and Synthesis Trans-
mission models do not allow individuals to start treatment
again in the implementation for this exercise. Eaton allows
individuals to restart treatment, but only once, and EMOD
allows half of individuals to restart treatment after they once
again satisfy the eligibility criterion.
Eleven of the models simulate the South African national HIV
epidemic, while the STDSIM model has been calibrated
specifically to the higher prevalence Hlabisa subdistrict of
KwaZulu-Natal Province, South Africa. Nine models were
calibrated to reproduce the historical time series of HIV
prevalence in South Africa, while the BBH, HIV Portfolio, and
Bendavid models were initialized using the current epidemic
state in the years 2009, 2011, and 2012, respectively, and
simulated forward from that point.
Most of the models were calibrated to yield a single set of
model parameters and outputs. Two of the models (Eaton
and STI-HIV Interaction) were calibrated using a Bayesian
framework allowing for uncertainty in model parameters,
which produces a joint posterior distribution of parameter
combinations consistent with the observed HIV epidemic
[43,84]. The STI-HIV Interaction model allows for uncertainty
in sexual behaviour, the natural history of HIV infection, and
the effect of ART, while the Eaton model only allows for
uncertainty in sexual behaviour and sexual mixing parame-
ters.
Many of the models include facilities to simulate HIV testing
and diagnosis, retention in care prior to treatment eligibility,
and other processes related to achieving successful treat-
ment, but these were not implemented for this exercise in
order to conform to the simple intervention scenarios.
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Scenarios Representing the Existing ART Programme in
South Africa
In a separate analysis, seven of the models (CD4 HIV/ART,
Eaton, Fraser, Goals, Granich, STDSIM, and STI-HIV Interac-
tion) were used to estimate the impact that the existing scale-up of
ART in South Africa has had on HIV incidence and prevalence
by comparing model simulations that include the ART scale-up
over the past decade with the no-ART counterfactual. Models
either used an existing calibration to the number of people on
ART in South Africa (Fraser and STDSIM) or were calibrated
using estimates of the number of adults starting and on ART in
each year from 2001 to 2011 [45] (CD4 HIV/ART, Eaton, Goals,
Granich, and STI-HIV Interaction).
Five models (Bendavid, CD4 HIV/ART, Eaton, Goals, and
Granich) constructed short-term projections of HIV incidence in
South Africa assuming different trajectories for continued ART
scale-up from 2011 to 2016, the period covered by South Africa’s
national strategic plan [46]. Starting from the number of patients
on ART in mid-2011, the numbers of adults starting ART in each
of the years from mid-2011 through mid-2016 was specified. A
‘‘baseline’’ scenario was considered in which 400,000 adults would
start ART in each of the next 5 y (approximately the number who
started ART in 2009), for a total of 2 million new adults initiating
ART. Three other scenarios were considered for the total numbers
starting ART over the same period: (i) ‘‘low’’—1.2 million start
ART; (ii) ‘‘medium’’—3 million start ART; and (iii) ‘‘high’’—3.9
million start ART. (The exact number starting in each year is
listed in Table 2.) The HIV incidence rate at the midpoint of 2016
and the cumulative number of new adult HIV infections over the
period 2011 to 2016 were reported for each of these scenarios. For
these projections, assumptions regarding CD4 distributions at
ART initiation and rates of retention were based on actual
treatment guidelines and programme experiences, but were not
standardised across models.
Results
Figure 1 shows HIV prevalence and HIV incidence in 15- to 49-
y-old males and females simulated by each of the models under the
counterfactual assumption of no ART provision.
Other epidemiologic statistics are presented in Table 3. The
estimates of adult male HIV prevalence in year 2012 ranged
between 10% and 16%, and estimates of female prevalence
between 17% and 23%. Male HIV incidence in year 2012 ranged
between 1.1 and 2.0 per 100 person-years, and female incidence
ranged between 1.7 and 2.6. The STDSIM model calibrated to
KwaZulu-Natal Province simulated a considerably larger burden
of HIV, consistent with observation [47], with prevalences in year
2012 of 23% and 33% in males and females, respectively, and
incidence rates of 3.0 and 3.9 per 100 person-years, respectively.
All of the sex-stratified models simulated higher HIV prevalence in
adult women than in men, with sex ratios in HIV prevalence in
year 2012 between 1.2 and 1.7, and all of the models except for
Bendavid simulated higher incidence in year 2012 in females than
in males.
Nearly all of the models projected declines in HIV incidence
after 2012 in the absence of ART, but the magnitude of the
projected natural changes between 2012 and 2050 varied widely
from almost no change (Goals and Granich) to greater than 45%
reduction (Bendavid and Synthesis Transmission).
Model projections of future national population growth in the
absence of ART varied widely, ranging from a 6% reduction to a
13% increase in the population aged 15 y and older between the
years 2012 and 2020. For comparison, the low and high variants
for the projected total population growth from the United Nations
Population Division over the same period (which incorporates
some assumptions about ART provision) are 1.5% and 6.1% [48].
Impact of ART on HIV Incidence
Figure 2 presents the outcomes of an intervention starting in
year 2012 with ART eligibility at CD4 count #350 cells/ml,
reaching 80% of those requiring treatment, and retaining 85% of
patients on ART after 3 y. This scenario reflects an optimised
implementation of the current World Health Organization
treatment guidelines [39] and the Joint United Nations Pro-
gramme on HIV/AIDS definition for ‘‘universal access’’ of
reaching 80% of those in need [32]. Compared to the no-
treatment counterfactual scenario, ART provision reduced inci-
dence in year 2020 by 35% to 54% across all models (Figure 2A).
There was much greater variation, however, in the estimated long-
term impact of the intervention. In year 2050, the range of the
predicted reduction in incidence was from 32% to 74%. The
relative impact of the ART intervention on HIV incidence
decreased between 2020 and 2050 in four models and increased in
seven.
Number of Person-Years of ART per Infection Averted
There was considerable variation between models in estimates
of the number of person-years of treatment per infection averted.
For the scenario described above, the range of estimates for the
number of person-years of ART per infection averted between
2012 and 2020 was between 6.3 and 18.7, and over the period
2012 to 2050, the range was 4.5 to 20.2 (Figure 2B). The four
models with the greatest estimates of the number of person-years
of ART provided per infection averted (Eaton, EMOD, STI-HIV
Interaction, and Synthesis Transmission) all explicitly included
variation in transmission by age (e.g., allowing for reduced impact
Table 2. Number of adults starting ART each year in the short term.
Year ‘‘Low’’ Future Scale-Up ‘‘Baseline’’ Future Scale-Up ‘‘Medium’’ Future Scale-Up ‘‘High’’ Future Scale-Up
2012 400,000 400,000 600,000 800,000
2013 200,000 400,000 600,000 900,000
2014 200,000 400,000 600,000 900,000
2015 200,000 400,000 600,000 700,000
2016 200,000 400,000 600,000 600,000
Total 1,200,000 2,000,000 3,000,000 3,900,000
Number of adults (age 15 y and older) initiating ART between midpoint of the previous year and the midpoint of indicated year.
doi:10.1371/journal.pmed.1001245.t002
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through ART provision to older adults who are less sexually active
and hence less likely to expose susceptible individuals), whereas the
other models did not assume reduced transmission by older people.
(STDSIM allows for decreased sexual activity for those older than
50 and has the lowest estimate of person-years of ART per infection
averted, but simulates a much higher HIV incidence.)
Determinants of Programme Impact
The impact on incidence of increasing access from 50% to
100%, improving 3-y programme retention from 85% to 100%,
and changing the CD4 threshold for treatment eligibility, is
shown for each model in Figure 3. The reduction in incidence
increases approximately linearly with access in all models. In
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most models, improvements in retention in care led to greater
impact of treatment on HIV incidence. The benefit of improving
retention was minimal for the Fraser, Granich, and HIV Portfolio
models. Each of these models regards individuals who have
dropped out of treatment identically to untreated eligible
individuals, allowing them to start treatment again on average
within 1 y. In several models, improved retention means that the
impact improves more rapidly with increasing access (i.e., the
slope in reduction in incidence as access increases is steeper for
higher retention).
Figure 4 shows how the number of person-years of ART
provided per infection averted up to year 2020 varied in relation to
the intervention programme. There were no consistent trends
across all models. In some models, with earlier initiation of
treatment, fewer years of ART were required per infection averted
(efficiency increases), whereas the opposite was predicted in others.
0 20 40 60 80 100
Year 2020A
STI−HIV
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Synthesis
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Figure 2. Impact of treatment for a scenario with eligibility at CD4#350 cells/ml, 80% access, and 85% retention. (A) The percentage
reduction in HIV incidence in the years 2020 and 2050 when eligibility for treatment is at CD4 count#350 cells/ml, 80% of individuals are treated, and
85% are retained on treatment after 3 y. (B) The cumulative number of person-years of ART provided per infection averted for the same scenario.
Horizontal lines indicate 95% credible intervals (CI). For the Bendavid model, results in year 2040 are reported in the right panels.
doi:10.1371/journal.pmed.1001245.g002
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For all of the models except the Granich model, which does not
include increased transmissibility during late-stage infection, it
might be expected that treating at lower CD4 count would be
more efficient, as it targets treatment towards individuals with the
highest current infectiousness (as in the BBH, Bendavid, CD4
HIV/ART, Eaton, and Goals models). However this could be
counteracted if stage of infection interacts with other processes
such as decreased propensity to form new partnerships with
ageing. For half of the models (BBH, Eaton, EMOD, Fraser,
Goals, Granich, and HIV Portfolio), increasing the percentage of
the population with access to treatment reduced the amount of
treatment per infection averted, at least at earlier CD4 initiation
thresholds. This increased efficiency is indicative of increasing
returns due to ‘‘herd immunity’’ at high intervention coverage
levels.
Treatment Eligibility and the Theoretical Impact of ‘‘Test
and Treat’’
The models varied in their predictions as to the relative benefit
of increasing treatment eligibility from a CD4 threshold of #200
cells/ml (national guidelines in some settings and close to actual
experience in many) to #350 cells/ml (international guidelines)
compared to further increasing eligibility to all infected individuals
(Figure 3). The Bendavid, CD4 HIV/ART, Goals, HIV Portfolio,
and Synthesis Transmission models all predicted that there would
be only a relatively modest benefit in moving from initiation at
#200 cells/ml to #350 cells/ml, and a much greater benefit in
moving from initiation at #350 cells/ml to immediately upon
diagnosis of HIV infection. In contrast, the BBH model simulated
very little benefit in moving from the #350 cells/ml threshold to
immediate eligibility. The Eaton, Fraser, and EMOD models
showed similar benefits associated with each of the increments at
moderate levels of access.
One important argument that has been made for immediate
ART is that commitment of a large amount of ART now could
reduce the cumulative amount of ART required in the future as a
result of averted HIV infections [2,49]. Whether such savings
could occur was evaluated by investigating whether the cumulative
person-years of treatment through year 2050 to implement
immediate treatment is less than the amount of ART required
when treating after the CD4 count falls below 350 cells/ml for the
same levels of access and retention. In six (BBH, CD4 HIV/ART,
Fraser, Goals, HIV Portfolio, and STDSIM) out of eleven models
(excluding STI-HIV Interaction) this was not the case: increasing
eligibility from CD4#350 cells/ml to immediate initiation always
required more person-years of treatment, even with ‘‘perfect’’
ART programmes (100% access and 100% retention). However,
for the EMOD model, expanding eligibility from CD4#350 cells/
ml to all HIV-infected adults required fewer cumulative person-
years of treatment in all intervention scenarios (including access as
low as 60% and retention in care as low as 75%). The Synthesis
Transmission model found expanding access to be ART-saving
with 70% access and retention above 95%, or with 80% access
and retention above 85%. The other three models that found that
expanding access could be ART-saving required more demanding
assumptions about programmes: according to the Granich model,
immediate initiation would be ART-saving if access were above
90% and retention above 95%; according to the Eaton model,
access and retention would need to exceed 95%; and according to
the Bendavid model, access and retention would both need to be
100%.
In an intervention treating all HIV-infected adults with 95%
access and 95% retention, three (CD4 HIV/ART, EMOD, and
HIV Portfolio) out of nine models (excluding BBH, Bendavid, and
STI-HIV Interaction) predicted that HIV incidence would fall
below 0.1% per year by 2050. The Granich model, which was
used to argue the case for HIV elimination using treatment,
projected that incidence in South Africa would be 0.13% under
this scenario, a 92% reduction (in the original published
projections, there was an assumption that risk of infection would
fall by an additional 40% due to other interventions [34]).
Understanding Differences between Model Predictions
One factor expected to influence how much ART reduces HIV
is the fraction of all transmission that occurs after individuals reach
treatment eligibility thresholds, in the absence of any treatment
[50]. Figure 5A shows the proportion of transmissions that occur
from individuals in each CD4 count range in the counterfactual
simulation in year 2012. Of the models that include a period of
early infection, the percentage of new infections that occurs during
this stage is between 4% and 28%, while between 20% and 51% of
transmission results from individuals with CD4 cell count #200
cells/ml.
These percentages of transmission after ART eligibility can be
compared with the percentage reduction in incidence in year 2020
(Figure 5B). Here, it is assumed that access is 80% and 3-y
retention in care is 85%. Although this comparison explains why,
within one model, earlier treatment initiation reduces HIV
incidence more, the amount of between-model variation in
projected impact explained by the distribution of transmission by
CD4 count is modest. R2 values for this relationship were 0.28,
0.20, and 0.40 for eligibility at CD4#200, eligibility at CD4#350,
and immediate eligibility, respectively. The correlation did not
improve when considering higher access or higher retention
scenarios.
Two other factors hypothesized to explain the differences
between the model projections are different assumptions about the
efficacy of ART in reducing transmission—between 90% and
99%—and different assumptions about the outcomes of individ-
uals who drop out from treatment programmes. To test the
importance of these factors, selected intervention scenarios were
repeated under the artificial assumption that an individual never
transmits after initiating treatment (treatment is 100% efficacious
at preventing transmission, and retention on treatment is 100%).
This assumption increased the intervention impact in every
model, but, surprisingly, did not reduce the variation in the
results between models or improve the ability of factors such as
different model assumptions about CD4 progression, HIV
transmission, or the future trajectory of HIV incidence to explain
the variation.
Estimates of the Current Impact of ART in South Africa
Figure 6 shows the estimated impact of the current ART
programme in South Africa on HIV prevalence and incidence.
The CD4 HIV/ART, Eaton, Goals, Granich, and STI-HIV
Interaction models used estimates of the number of adults
starting treatment in South Africa in each year between 2001
and 2011 from [45], and the Fraser and STDSIM models used
Figure 3. Proportion reduction in HIV incidence in year 2020. For each model, the proportion reduction in HIV incidence in year 2020 for
increasing access levels from 50% to 100% (horizontal axis). ART eligibility thresholds are indicated by line colour; 85% retention is indicated by solid
lines, and perfect 100% retention is indicated by dashed lines.
doi:10.1371/journal.pmed.1001245.g003
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existing calibrations to ART coverage levels in the Western
Cape and KwaZulu-Natal Provinces, respectively. All of the
models predicted that ART should already have had a
substantial impact on the HIV epidemic, estimating that HIV
incidence in year 2011 was between 17% and 32% lower than it
would have been in the absence of ART. The increasing impact
on HIV incidence over time mirrors the steep increase every
year in the number of people starting treatment during this
period.
The impact on prevalence was more modest and less consistent
across models. The Eaton and STI-HIV Interaction models
estimated that prevalence is around 8% higher than it would have
been without treatment (an absolute increase in prevalence of one
percentage point) due to the increased survival for those infected
with HIV. The Fraser and Granich models suggest that this effect
is offset by the reductions in incidence, so that there is no net
change in prevalence. It is unlikely that standard surveillance
methods based on monitoring trends in prevalence would have
detected this impact, despite the significant underlying reductions
in incidence.
The estimated potential impact of further ART scale-up is
summarised in Table 4. In the baseline scenario, where 400,000
people are started on ART each year, the models estimated that
incidence would be reduced in 2016 by between 13% and 26%
compared to the incidence rate in 2011. If 800,000 fewer people
are put on ART, then between 39,000 and 186,000 more new
adult HIV infections would occur over the period 2012 to 2016
than under the baseline scenario. If more people are put on
ART—3.0 or 3.9 million over the next 5 y—then the models
estimated that the number of new infections over the 5-y period
would be reduced by 64,000 to 327,000 and 270,000 to 521,000,
respectively, compared to the baseline. The table underscores that
there are still substantial potential preventive benefits from
expanding ART coverage in South Africa. The models that
tended to estimate the greatest reduction in incidence in
hypothetical programmes over the medium term (CD4 HIV/
ART, Goals, and Granich) also tended to project greater
reductions in incidence over the short term in these more realistic
scenarios.
Discussion
The mathematical models used to simulate the impact of
treatment on HIV incidence in South Africa are diverse in their
structure, level of complexity, representation of the HIV transmis-
sion process and the ART intervention, and parameter choices. All
twelve of the models compared in this analysis predicted that
treatment could substantially reduce HIV incidence—even using
past or existing treatment guideline eligibility criteria, provided that
coverage is high. Only three (CD4 HIV/ART, EMOD, and HIV
Portfolio) out of nine models (excluding BBH, Bendavid, and STI-
HIV Interaction), however, predicted that treatment could reduce
HIV incidence below 0.1% by year 2050 (the definition of
‘‘elimination’’ established by [34]), even with very high access and
Figure 4. Cumulative number of person-years of ART provided per infection averted through year 2020. The cumulative person-years of
ART provided per infection averted through the year 2020 for increasing access levels from 50% to 100% (horizontal axis), assuming 85% retention after
3 y. ART eligibility thresholds of are indicated by line colour. Varying retention did not affect trends between access and efficiency for any models.
doi:10.1371/journal.pmed.1001245.g004
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retention. When simulating the historical scale-up of ART in South
Africa, the models indicated that ART may already have reduced
HIV incidence by between 17% and 32% in 2011, compared to
what would have been expected in the absence of ART.
Although there have been ad hoc informal model comparison
exercises [51], collections of work using standardised assumptions
for interventions [52], and thorough model comparisons involving
a few research groups [53,54], to our knowledge, this exercise is
the first to bring together such a large number of independent
modelling groups to examine the same set of interventions. We
hope that this will provide a foundation for much more
collaborative work.
In this study we set out to test whether different models of the
potential impact of treatment on new HIV infections in South
Africa would make similar predictions when implementing the
same intervention scenarios. We found substantial consistency
between the model projections of the impact of ART interventions
on HIV incidence in the short term (8 y). However, there was
more variation in the predicted longer term (38 y) reductions in
incidence, and models also produced divergent estimates of the
number of person-years of ART provided per infection averted.
While establishing where models agree and disagree about the
epidemiological impact of ART represents an important scientific
finding in itself, the substantial variation in the long-term impact
and efficiency of interventions demands further investigation and
explanation.
Based on epidemiological theory and previous modelling
studies, we hypothesized a number of model attributes that might
explain differences in model predictions about the impact of ART,
including the amount of transmission in different stages of HIV
infection, the assumed efficacy of ART for preventing transmis-
sion, opportunities for treatment reinitiation following dropout
from a treatment programme, the age and sex structure of the
population, future population growth rates, the degree of
heterogeneity and assortativity in sexual mixing, the future
trajectory of HIV incidence in the absence of intervention, and
the inclusion of changes in sexual behaviour over the past decade.
There was indeed substantial variation between the models in their
characterisation of each of these aspects of the system, largely
reflecting the true uncertainties that persist even after decades of
tremendous research into the epidemiology of HIV in South
Africa. We were able to show that crude differences in the
proportion of transmission at each stage of infection explained a
modest amount of the variation in the short-term impact of ART,
but less of the long-term impact. However, beyond this, findings
from the models did not appear to clearly support any of these
hypotheses in univariate analyses, likely because of the large
number of processes that interact nonlinearly to create HIV
epidemics and interventions. For example, projecting a seemingly
simple quantity such as the number of person-years of ART that
will be provided in an intervention depends on future population
growth, the natural trend in the epidemic, the proportion of HIV-
infected individuals qualifying for treatment, retention and
survival on ART, and the impact that ART provision has on
future HIV incidence. This situation contrasts with that of an
earlier exercise that compared predictions of the impact of male
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circumcision interventions [51], where the relationship between
the established efficacy of the intervention and population-level
impact was less complicated.
Having investigated the extent to which differences in ART
programmes determine differences in results, the natural focus for
future model comparison studies should be to explore the
contribution of other hypotheses through incrementally standard-
ising biological, behavioural, and demographic model parameters,
and calibrating models to the same levels of HIV prevalence and
incidence. A systematic approach to standardising model param-
eters would identify which parameters most significantly influence
the results and guide priorities for future data collection. The HIV
Modelling Consortium (http://www.hivmodelling.org) will coor-
dinate such research efforts in coming months to investigate the
extent to which variation in model predictions is driven by
differences in underlying models of sexual mixing, or different
models of the natural history of infection and epidemic trajectory.
Although our experiment and analysis has focused on how
factors included in models can affect model predictions, it is
important to note that if all models exclude an important aspect of
the system, they could all be wrong. Early models of the impact of
ART on HIV incidence were very focused on the concern that
increased sexual risk behaviour might offset the reduction in
transmission for those on treatment, but for this exercise all of the
models assumed that population risk behaviour would not change
in response to the introduction of ART. This may be a reasonable
assumption given consistent evidence that patients report safer
sexual behaviour after starting ART [55–59] and given the relative
lack of information from sub-Saharan Africa about how the
untreated and HIV-negative population responds to the availabil-
ity of treatment [60]. But in other epidemic settings the availability
of ART has been associated with receding gains in protective
behaviour [61–63], and monitoring this in sub-Saharan African
settings will be a priority for surveillance over coming years. The
models also all assumed high efficacy of ART to reduce
transmission. True effectiveness will depend on adherence and
the level of viral suppression, which is mainly determined by
adherence levels. While there are some data from South Africa on
viral suppression rates outside carefully controlled trial settings
[64], further information on this and on patterns of acquired and
transmitted resistance will help in the calibration of models. Only
one of the models in this exercise (Synthesis Transmission)
explicitly incorporated the effect of antiretroviral drug resistance
on the impact of ART interventions. Models have predicted that
antiretroviral drug resistance could be widespread in sub-Saharan
Africa in coming decades [20], which could eventually lead to the
spread of transmitted drug resistance [65,66]. This could affect the
long-term costs and efficacy of treatment-as-prevention strategies
[67].
Another finding from systematically comparing models is that
often seemingly independent modelling studies rely on the same
limited data. Nearly all of the models relied on two sources to
derive parameters for elevated infectiousness during the first few
weeks of infection [68,69], but both of these sources are based
principally on data from a few retrospective couples in Rakai,
Uganda [70] (see [71]). This highlights both how invaluable these
data are and also the importance of recognising the dependencies
between seemingly independent modelling studies. However, even
using the same data, models may reach different conclusions. The
Eaton, EMOD, and Fraser models all in some way used the
estimates of early HIV infectivity from [69] but estimate very
different contributions of this stage to overall HIV transmission
(Figure 4A), and the three models all reached different conclusions
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from those in another recent modelling study relying on these
same estimates [72].
The purpose of this exercise was not to draw conclusions or
recommendations about specific ART intervention strategies, but
rather to test the hypothesis that a range of different models would
come to similar conclusions about the impact of ART on HIV
incidence when the same interventions were modelled. The
simulated interventions were artificially simple and stylized to
enable comparison between models. These did not explicitly
simulate the steps of HIV testing, diagnosis, linkage to care, and
adherence to ART required to achieve the access levels specified in
the intervention scenarios (although several of the models include
facility for this and have investigated this in independent analyses).
Interpretation of models simulating high levels of treatment
coverage should be cautioned by data suggesting that at present
fewer than one-third of patients in sub-Saharan Africa are
continuously retained in care from HIV diagnosis to ART
initiation [73], and that barriers remain to access to and uptake
of HIV testing [32]. The models assumed that all individuals
eligible for treatment were equally likely to access treatment,
which might not be true in practice (for example, women are more
likely to start treatment than men [74]). The comparison scenario
(counterfactual) against which interventions were evaluated
assumed no treatment at all, which made it easier to compare
models, but is clearly not the relevant benchmark for policy-
makers. This study has also considered treatment in isolation from
other interventions, even as there is broad consensus that
‘‘combination prevention’’ strategies are presently the best strategy
for attacking the epidemic [41,75].
We hope that this study will help to characterise the models that
are being used to investigate questions related to the impact of
HIV treatment and enable those who rely on models for decision-
making to think critically about how the assumptions underlying
models affect the results. The relative consistency between models’
estimates of the short-term epidemiological impact of ART,
including the impact of the existing ART programme, provides
some reassurance that model projections on this time scale may be
relatively robust to the substantial uncertainties in parameters and
systems. This is a significant result considering that such short-
term projections are often the most relevant for policy and
resource allocation questions. On the other hand, the substantial
variation in long-term epidemiological impacts and efficiency of
ART, upon which arguments of substantial epidemic reduction
and cost savings hinge, suggests that results in these areas from any
single model should be extrapolated with caution. Care should be
taken to ensure that models evaluating the long-term costs,
benefits, and cost-effectiveness of treatment programmes ade-
quately communicate the degree and myriad sources of uncer-
tainty that influence these outputs.
A common question when faced with a diversity of model results
is whether some models are ‘‘better’’ or ‘‘worse’’. Without data
against which to test the predictions of models, it is not possible to
answer this question in a study such as this, nor is this the correct
question to be asking. Rather, users of model outputs should ask
whether models include the necessary components to capably
answer the specific questions at hand, and whether the models
make credible assumptions in light of the information available,
and choose models accordingly. Evaluated along these guidelines,
the most appropriate models will vary between applications, so
there is no single ‘‘best’’ model. However, in this exercise, the
models that tended to project more ‘‘pessimistic’’ outcomes for the
interventions seemed to do so for important reasons. For example,
models that estimated poorer efficiency of ART for averting
infections tended to be those that simulated ART provision for
those at older ages, who might be at lower risk of transmitting, or
included the elevated risk of transmission for those failing
treatment, whereas models with more optimistic predictions
assumed that risk behaviour did not vary by age or that
transmission was fully suppressed immediately upon beginning
treatment until death on ART or dropout. Artificial convergence
of models should be avoided when true uncertainties persist about
the system. It is incumbent upon modellers to incorporate and
communicate uncertainty in projections, and identify which
components of the system account for the uncertainty. For this
exercise, only one model (STI-HIV Interaction) included a
comprehensive analysis accounting for uncertainty about basic
epidemiology and intervention efficacy. While the focus of the
study was on variation between models, it is interesting to observe
that the 95% credible interval representing parameter uncertainty
for this model encompassed the point estimates of the other eleven
models.
Fortunately there will be important new opportunities in the
near future to test, validate, and improve epidemiological models
of HIV treatment. These include comparing projections to the
experience of expanded ART in industrialised countries [61,63],
the observed impact of ART in well-characterised communities
[76], and results of a number of community-randomized trials of
treatment as prevention that will soon be underway [44]. As new
data are reported, the accuracy of models projecting the impact of
treatment as prevention should improve, and we expect that
validated and scientifically based model projections will continue
to be central in understanding how ART can have the greatest
impact in mitigating the global HIV epidemic.
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Editors’ Summary
Background. Following the first reported case of AIDS in
1981, the number of people infected with HIV, the virus that
causes AIDS, increased rapidly. In recent years, the number of
people becoming newly infected has declined slightly, but
the virus continues to spread at unacceptably high levels. In
2010 alone, 2.7 million people became HIV-positive. HIV,
which is usually transmitted through unprotected sex,
destroys CD4 lymphocytes and other immune system cells,
leaving infected individuals susceptible to other infections.
Early in the AIDS epidemic, half of HIV-infected people died
within eleven years of infection. Then, in 1996, antiretroviral
therapy (ART) became available, and, for people living in
affluent countries, HIV/AIDS gradually became considered a
chronic condition. But because ART was expensive, for
people living in developing countries HIV/AIDS remained a
fatal condition. Roll-out of ART in developing countries first
started in the early 2000s. In 2006, the international
community set a target of achieving universal ART coverage
by 2010. Although this target has still not been reached, by
the end of 2010, 6.6 million of the estimated 15 million
people in need of ART in developing countries were
receiving ART.
Why Was This Study Done? Several studies suggest that
ART, in addition to reducing illness and death among HIV-
positive people, reduces HIV transmission. Consequently,
there is interest in expanding the provision of ART as a
strategy for reducing the spread of HIV (‘‘HIV treatment as
prevention’’), particularly in sub-Saharan Africa, where one in
20 adults is HIV-positive. It is important to understand
exactly how ART might contribute to averting HIV transmis-
sion. Several mathematical models that simulate HIV
infection and disease progression have been developed to
investigate the impact of expanding access to ART on the
incidence of HIV (the number of new infections occurring in
a population over a year). But, although all these models
predict that increased ART coverage will have epidemiologic
(population) benefits, they vary widely in their estimates of
the magnitude of these benefits. In this study, the
researchers systematically compare the predictions of 12
mathematical models of the HIV epidemic in South Africa,
simulating the same ART intervention programs to deter-
mine the extent to which different models agree about the
impact of expanded ART.
What Did the Researchers Do and Find? The researchers
invited groups who had previously developed mathematical
models of the epidemiological impact of expanded access to
ART in South Africa to participate in a systematic comparison
exercise in which their models were used to simulate ART
scale-up scenarios in which the CD4 count threshold for
treatment eligibility, access to treatment, and retention on
treatment were systematically varied. To exclude variation
resulting from different model assumptions about the past
and current ART program, it was assumed that ART is
introduced into the population in the year 2012, with no
treatment provision prior to this, and interventions were
evaluated in comparison to an artificial counterfactual
scenario in which no treatment is provided. A standard
scenario based on the World Health Organization’s recom-
mended threshold for initiation of ART, although unrepre-
sentative of current provision in South Africa, was used to
compare the models. In this scenario, 80% of HIV-infected
individuals received treatment, they started treatment on
average a year after their CD4 count dropped below 350 cells
per microliter of blood, and 85% remained on treatment
after three years. The models predicted that, with a start
point of 2012, the HIV incidence would be 35%–54% lower in
2020 and 32%–74% lower in 2050 compared to a counter-
factual scenario where there was no ART. Estimates of the
number of person-years of ART needed per infection averted
(the efficiency with which ART reduced new infections)
ranged from 6.3–18.7 and from 4.5–20.2 over the periods
2012–2020 and 2012–2050, respectively. Finally, estimates of
the impact of ambitious interventions (for example, imme-
diate treatment of all HIV-positive individuals) varied widely
across the models.
What Do These Findings Mean? Although the mathe-
matical models used in this study had different characteris-
tics, all 12 predict that ART, at high levels of access and
adherence, has the potential to reduce new HIV infections.
However, although the models broadly agree about the
short-term epidemiologic impact of treatment scale-up, their
longer-term projections (including whether ART alone can
eliminate HIV infection) and their estimates of the efficiency
with which ART can reduce new infections vary widely.
Importantly, it is possible that all these predictions will be
wrong—all the models may have excluded some aspect of
HIV transmission that will be found in the future to be
crucial. Finally, these findings do not aim to indicate which
specific ART interventions should be used to reduce the
incidence of HIV. Rather, by comparing the models that are
being used to investigate the feasibility of ‘‘HIV treatment as
prevention,’’ these findings should help modelers and policy-
makers think critically about how the assumptions underly-
ing these models affect the models’ predictions.
Additional Information. Please access these websites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1001245.
N This study is part of the July 2012 PLoS Medicine Collection,
‘‘Investigating the Impact of Treatment on New HIV
Infections’’
N Information is available from the US National Institute of
Allergy and Infectious Diseases on HIV infection and AIDS
NAM/aidsmap provides basic information about HIV/AIDS
and summaries of recent research findings on HIV care and
treatment
N Information is available from Avert, an international AIDS
charity on many aspects of HIV/AIDS, including informa-
tion on HIV/AIDS treatment and care, on HIV treatment as
prevention, and on HIV/AIDS in South Africa (in English and
Spanish)
N The World Health Organization provides information about
universal access to AIDS treatment (in English, French, and
Spanish); its 2010 ART guidelines can be downloaded
N The HIV Modelling Consortium aims to improve scientific
support for decision-making by coordinating mathematical
modeling of the HIV epidemic
N Patient stories about living with HIV/AIDS are available
through Avert; the charity website Healthtalkonline also
provides personal stories about living with HIV, including
stories about taking anti-HIV drugs and the challenges of
anti-HIV drugs
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